CYP2C19‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients

CYP2C19‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients

ABSTRACT Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshiki Katada, Daiki Hira, Keisuke Umemura, Yurie Katsube, Hiroki Ishimura, Yusuke Kojima, Machiko Hirai, Moto Kajiwara, Mitsuhiro Sugimoto, Hiroki Endo, Junru Cao, Saki Ohta, Kinuka Kotani, Sakiko Hatazoe, Masahiro Tsuda, Shunsaku Nakagawa, Koh Shinohara, Yasuhiro Tsuchido, Miki Nagao, Tomohiro Terada
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Clinical and Translational Science
Subjects:
CYP2C19
genotype‐guided
pharmacogenomics
precision medicine
therapeutic drug monitoring
voriconazole
Online Access:https://doi.org/10.1111/cts.70317
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70317

Similar Items